INmune Bio, Inc. (INMB)

Over the past six months, INmune Bio's stock price has experienced significant volatility, with a notable decline. As of March 30, 2026, the stock price was $1.14 per share, representing an 85.40% decline over the past 12 months. Key events impacting the stock include the announcement of Q3 2025 results with successful completion of initial commercial pilot-scale manufacturing runs for CORDStrom™ and progress with XPro™ data submission. INmune Bio reported new Phase 2 grey matter imaging data at the CTAD Conference, reinforcing XPro1595's evidence base. The company issued a shareholder letter reviewing 2025 milestones and outlining 2026 strategic initiatives. INmune Bio announced FDA alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer's Disease. INmune Bio's MINDFuL Trial was featured at the AD/PD 2026 Plenary. The company announced its 2025 results, reporting a net loss of $45.9 million for 2025 and cash and cash equivalents of approximately $24.8 million, with an estimated cash runway through Q1 2027.

As a clinical-stage biotechnology company, INmune Bio, Inc. does not currently have commercial products on the market, and therefore, does not experience traditional demand seasonality for products and services. Its revenue drivers are research and development activities related to its clinical-stage drug candidates rather than commercial product sales. The company's financial performance and stock valuation are primarily driven by clinical trial milestones, regulatory progress, and financing activities, rather than seasonal consumer demand.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies targeting the innate immune system for neurodegenerative diseases and cancer. The company operates in the biopharmaceutical and immunotherapy industries, emphasizing conditions with chronic inflammation or immune dysfunction. As a pre-revenue company, its primary activities are research and development related to its clinical-stage drug candidates. INmune Bio has three main product platforms: DN-TNF Platform (XPro™/XPro1595/pegipanermin) utilizes dominant-negative technology to selectively neutralize soluble Tumor Necrosis Factor (TNF). Natural Killer (NK) Cell Priming Platform (INKmune®) is designed to prime a patient's natural killer cells to eliminate minimal residual disease in cancer patients. CORDStrom™ Platform is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal stromal/stem cell (hucMSCs) platform being developed for recessive dystrophic epidermolysis bullosa (RDEB).

INmune Bio is headquartered in Boca Raton, Florida, which serves as its primary executive and administrative center. The company's operational footprint is concentrated in North America, particularly the United States, where most of its research oversight, regulatory interaction, and clinical trial coordination occur. International activities are primarily limited to clinical research and scientific collaboration, with engagement in international clinical sites and research partners, but without a broad global commercial presence.

INmune Bio's brand reputation over the past year is primarily shaped by its clinical trial progress and regulatory interactions. The company announced the closing of an approximately $19 million registered direct offering. Phase II results for XPro in Alzheimer's disease failed to meet the primary cognitive endpoint. Continued positive updates on the CORDStrom™ platform, including successful manufacturing runs and planned regulatory submissions, as well as FDA alignment for XPro1595's adaptive Phase 2b/3 pathway in early Alzheimer's disease, have likely helped to rebuild confidence. The featuring of INmune Bio's MINDFuL trial at the AD/PD 2026 Plenary also suggests scientific recognition.

The ownership structure of INmune Bio (INMB) is a mix of institutional, insider, and retail investors. Institutional ownership ranges from approximately 5.44% to 21.21% of the shares outstanding. Insider ownership is around 11.17% to 17.48%. The remaining float, largely held by retail/public investors, is significant, estimated at around 71.34% to 77.60%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Geode Capital Management, Llc. Key individual insiders with significant holdings include Raymond Tesi and Mark Lowdell.